Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.61 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | LAP3 | P28838 | 1/20 | 0.55 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6364440 | 1.00 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL1168587 | 1.00 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL73707 | 0.98 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL73708 | 0.98 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL3099705 | 0.98 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Carbamic Acid SCHEMBL13836019 | 0.95 | SLC7A5 (0.59) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL9831417 | 0.94 | SLC7A5 (0.60) | SLC7A5ALPIPKMPTGS1XIAP | |
| Alcohol SCHEMBL28299118 | 0.94 | ALDH1A1 (0.54) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL9831421 | 0.94 | SLC7A5 (0.60) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL3828203 | 0.92 | SRR (0.54) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | claimed |
| CN-118007135-A | Corrosion inhibition method for inhibiting metal corrosion in sulfur-containing medium | 福建理工大学 | 2024-05-10 | — | — | CN | claimed |
| CN-106998771-B | Flavour composition and pet food comprising same | 马斯公司 | 2021-06-22 | — | — | CN | claimed |
| CN-107998453-B | Surface-modified acellular matrix and modification method thereof | 中山大学附属第一医院 | 2020-09-25 | — | — | CN | claimed |
| CN-109847455-A | A kind of composite material, preparation method and application for filtering fine particulates | 四川大学 | 2019-06-07 | — | — | CN | claimed |
| CN-109041999-A | A method of preventing pomegranate dehiscent fruit | 蚌埠市涂山村富民石榴专业合作社 | 2018-12-21 | — | — | CN | claimed |
| CN-109023938-A | A kind of colouring method of bamboo fiber fabric | 阜南美凯服饰有限公司 | 2018-12-18 | — | — | CN | claimed |
| CN-107998453-A | Surface-modified acellular matrix and modification method thereof | 中山大学附属第医院 | 2018-05-08 | — | — | CN | claimed |
| US-20250367299-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4630464-A1 | FUNCTIONALIZED AND NON-FUNCTIONALIZED AMPHIPHILIC POLYMERS BASED ON POLYACRYLIC ACID FOR THE SOLUBILIZATION, ISOLATION AND MOLECULAR LABELLING OF MEMBRANE PROTEINS IN AQUEOUS MEDIA | Cube Biotech GmbH (DE) | 2025-10-15 | — | — | EP | disclosed |
| US-12251445-B2 | Gamma-hydroxybutyrate delivering compounds and processes for making and using them | ZEVRA THERAPEUTICS, INC. | 2025-03-18 | — | — | US | disclosed |
| CN-113366011-B | Process for producing peptide compound | 日产化学株式会社 | 2024-08-16 | — | — | CN | disclosed |
| EP-4403042-A2 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3229612-B1 | USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-0266950-A2 | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1988-05-11 | — | — | EP | disclosed |
| CN-87101499-A | Preparation method of n-statinib and n-cyclostatini polypeptide | — | 1988-05-11 | — | — | CN | disclosed |
| US-4721726-A | ANALGESICS | SCHERING CORPORATION (US) | 1988-01-26 | — | — | US | disclosed |
| US-4610816-A | ANALGESICS | SCHERING CORPORATION (US) | 1986-09-09 | — | — | US | disclosed |
| EP-0103077-A2 | Substituted dipeptides, methods for their production, pharmaceutical compositions containing them, method for making such pharmaceutical compositions | SCHERING CORPORATION (US) | 1984-03-21 | — | — | EP | disclosed |
| US-3988341-A | Esterification process | MERCK & CO., INC. (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367299-A1 | GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM | HSD17B10, HSD17B12, HSD17B14 | PTGS1 1215/4885SLC6A2 962/4885SLC6A3 1039/4885 |
| US-12251445-B2 | Gamma-hydroxybutyrate delivering compounds and processes for making and using them | HSD17B10, HSD17B12, HSD17B14 | PTGS1 1215/4885SLC6A2 962/4885SLC6A3 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.